In the third quarter, Banyan Capital Management Inc. established a new position in Johnson & Johnson, acquiring 3,853 shares valued at approximately $714,000. This stake now represents 0.3% of Banyan’s portfolio and ranks as its 22nd largest holding. Other major investors also adjusted their exposure: Norway’s sovereign wealth fund initiated a $4.88 billion stake in Q2, Vanguard added roughly 3.09 million shares (1.3% increase) to reach 237.05 million shares, and Geode Capital Management increased its holding by 1.2 million shares (2.1% gain) to 60.61 million shares. Together, institutional investors now own nearly 70% of the company’s stock, underscoring broad-based confidence in J&J’s diversified healthcare franchises.

The Committee for Medicinal Products for Human Use delivered a favorable opinion for AKEEGA (niraparib plus abiraterone) in BRCA1/2-mutant metastatic hormone-sensitive prostate cancer. Approval in the EU would mark J&J’s entry into a new oncology revenue stream, with analysts estimating peak annual sales of up to $1 billion. This regulatory milestone not only diversifies the company’s pharmaceutical portfolio but also enhances its long-term growth outlook in a segment projected to expand at a 10%+ compound annual rate through 2030.

In its latest quarter, J&J reported revenue of $24.56 billion, a 9.1% year-over-year increase driven by strength across immunology and infectious-disease franchises. Adjusted EPS of $2.46 met consensus forecasts, while net margin expanded to 28.5%. The company raised its full-year 2026 EPS guidance to a range of $11.43–$11.63, implying mid‐single-digit growth over 2025. Management reiterated its commitment to return at least $37 billion to shareholders through dividends and share repurchases, maintaining a payout ratio below 50% and a dividend increase track record extending beyond six decades.

Following the Q4 results, several brokerages raised their outlooks on J&J. Daiwa Capital Markets upheld an Outperform rating and lifted its target by 5%, Morgan Stanley upgraded to Overweight citing an improved growth trajectory, and Scotiabank reiterated Outperform while boosting its target by more than 10% after solid quarterly metrics. The consensus among 26 analysts now skews toward Buy, with a moderate-buy average rating and target revisions that imply upside of mid-to-high single digits from current levels.